BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1130 related articles for article (PubMed ID: 1373688)

  • 1. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
    La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
    Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell factor (c-kit ligand) enhances the interleukin-9-dependent proliferation of human CD34+ and CD34+CD33-DR- cells.
    Lemoli RM; Fortuna A; Fogli M; Motta MR; Rizzi S; Benini C; Tura S
    Exp Hematol; 1994 Aug; 22(9):919-23. PubMed ID: 7520394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor.
    Lemoli RM; Fogli M; Fortuna A; Motta MR; Rizzi S; Benini C; Tura S
    Exp Hematol; 1993 Dec; 21(13):1668-72. PubMed ID: 7694867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human interleukin (IL)-9 specifically stimulates proliferation of CD34+++DR+CD33- erythroid progenitors in normal human bone marrow in the absence of serum.
    Lu L; Leemhuis T; Srour EF; Yang YC
    Exp Hematol; 1992 May; 20(4):418-24. PubMed ID: 1373687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.
    Ottmann OG; Stella CC; Eder M; Reutzel P; Ströcker S; Hoelzer D; Ganser A
    Exp Hematol; 1991 Sep; 19(8):773-8. PubMed ID: 1714403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture.
    Simmons PJ; Aylett GW; Niutta S; To LB; Juttner CA; Ashman LK
    Exp Hematol; 1994 Feb; 22(2):157-65. PubMed ID: 7507857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of erythropoiesis and myelopoiesis by exogenous erythropoietin in human long-term marrow cultures.
    Mayani H; Guilbert LJ; Janowska-Wieczorek A
    Exp Hematol; 1990 Mar; 18(3):174-9. PubMed ID: 2303109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of stem cell factor on myelopoiesis potential in human Dexter-type culture systems.
    Liesveld JL; Broudy VC; Harbol AW; Abboud CN
    Exp Hematol; 1995 Mar; 23(3):202-9. PubMed ID: 7533098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells.
    Traycoff CM; Abboud MR; Laver J; Brandt JE; Hoffman R; Law P; Ishizawa L; Srour EF
    Exp Hematol; 1994 Feb; 22(2):215-22. PubMed ID: 7507862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
    Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
    Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells.
    Miller CL; Rebel VI; Lemieux ME; Helgason CD; Lansdorp PM; Eaves CJ
    Exp Hematol; 1996 Feb; 24(2):185-94. PubMed ID: 8641340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and characterization of early hematopoietic progenitors using an anti-CD71/S06 immunotoxin.
    Benedetti G; Bondesan P; Caracciolo D; Cherasco C; Ruggieri D; Gastaldi ME; Pileri A; Gianni AM; Tarella C
    Exp Hematol; 1994 Feb; 22(2):166-73. PubMed ID: 7507858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow.
    Slanicka Krieger M; Nissen C; Manz CY; Toksoz D; Lyman SD; Wodnar-Filipowicz A
    Exp Hematol; 1998 May; 26(5):365-73. PubMed ID: 9590652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mast cell growth factor, interleukin-3, and interleukin-6 on human primitive hematopoietic progenitors from bone marrow and cord blood.
    Tsujino Y; Wada H; Misawa M; Kai S; Hara H
    Exp Hematol; 1993 Sep; 21(10):1379-86. PubMed ID: 7689484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
    Van Epps DE; Bender J; Lee W; Schilling M; Smith A; Smith S; Unverzagt K; Law P; Burgess J
    Blood Cells; 1994; 20(2-3):411-23. PubMed ID: 7538347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fetal bone marrow CD34+CD41+ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells.
    Murray LJ; Mandich D; Bruno E; DiGiusto RK; Fu WC; Sutherland DR; Hoffman R; Tsukamoto A
    Exp Hematol; 1996 Feb; 24(2):236-45. PubMed ID: 8641347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM; Gulati SC
    Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive stem cell selection--basic science.
    Civin CI; Strauss LC; Fackler MJ; Trischmann TM; Wiley JM; Loken MR
    Prog Clin Biol Res; 1990; 333():387-401; discussion 402. PubMed ID: 1689854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.